The global tumor necrosis factor inhibitor drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027). New product launches, a promising pipeline, an increase in the incidence of autoimmune diseases, and a large increase in consumer knowledge of tumor necrosis factor are likely to fuel the growth (TNF) of the market. TNF inhibitors are used to treat inflammatory and autoimmune disorders such as rheumatoid arthritis, psoriasis, Crohn's disease, and cancer, among others, by suppressing the inflammatory response generated by TNF cytokines. The role of TNF inhibitors in the treatment of metastatic melanomas and locally progressed soft tissue sarcomas is under research. Biosimilars provide a direct challenge to biologics in the TNF inhibitor market.
Biosimilars are becoming more common due to the loss of patent exclusivity in several regions. In addition, Interleukin (IL) inhibitors are a fierce competitor in the market. In multiple head-to-head clinical trials, IL inhibitors have been shown to have improved safety and effectiveness profiles, as well as superior results. A considerable paradigm shift in the treatment of autoimmune disorders has been noted, owing to biologics' focused activity and the emergence of biosimilars. Consumer desire for low-cost pharmaceuticals with enhanced safety and efficacy profiles is likely to boost the market growth.
Market Coverage
Competitive Landscape: AbbVie Inc.; Johnson & Johnson Services, Inc.; Novartis International AG; Pfizer, Inc.; and Merck & Co., Inc among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Tumor Necrosis Factor Inhibitor Drugs Market Report Segmentation
By Product
• Humira
• Enbrel
• Remicade
• Simponi
• Cimzia
• Others
By Application
• Rheumatoid Arthritis
• Psoriasis
• Psoriatic Arthritis
• Crohn’s Disease
• Ulcerative Colitis
• Others
Global Tumor Necrosis Factor Inhibitor Drugs Market by Region
North America
Europe
Asia-Pacific
Rest of the World